Loading...

Home
Stock
ROIV

ROIV News & Events

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Stock Price Prediction Technical Valuation Financials Earnings Should I Buy News & Events

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

ROIV News

Roivant Sciences Q4 2025 Earnings Call Insights Highlight Key Developments

May 20 2026seekingalpha

Roivant (ROIV) Q4 2025 Earnings Transcript

May 20 2026NASDAQ.COM

Roivant Sciences Releases Preliminary Data from 1402 Study

May 20 2026Yahoo Finance

Roivant Sciences Reports $355.7M Net Income, Shares Surge

May 20 2026stocktwits

Immunovant's Phase 2 Trial Results Show Promising Efficacy for IMVT-1402

May 20 2026seekingalpha

Roivant Sciences Q4 Earnings Beat Expectations

May 20 2026seekingalpha

Roivant Sciences to Announce Q4 Earnings on May 20

May 19 2026seekingalpha

Moderna Surpasses Q1 Revenue Estimates Driven by International Vaccine Sales

May 01 2026Newsfilter

ROIV Events

No data

No data

ROIV Monitor News

Roivant Sciences Q4 Earnings Beat Expectations

Brepocitinib Shows Significant Benefits in Dermatomyositis Trial

Roivant Sciences benefits from Moderna's patent settlement

Roivant Sciences Stock Soars on Positive Phase 2 Results for Brepocitinib

Roivant Sciences Reports Positive Phase 2 Results for Brepocitinib

Roivant Sciences reaches 5-day high amid market fluctuations

Roivant Sciences Ltd sees stock drop amid market strength

Roivant Sciences Ltd reaches 52-week high amid sector rotation

ROIV Earnings Analysis

Roivant Sciences Earnings & Drug Discoveries Update- Intellectia AI™

Roivant Sciences Shows Resilience with Strategic Advancements - Intellectia AI™

Roivant Reports Second Quarter Financial Results for 2024

People Also Watch